Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rostam, Namdari"'
Autor:
JP Johnson, Thilo Focken, Kuldip Khakh, Parisa Karimi Tari, Celine Dube, Samuel J Goodchild, Jean-Christophe Andrez, Girish Bankar, David Bogucki, Kristen Burford, Elaine Chang, Sultan Chowdhury, Richard Dean, Gina de Boer, Shannon Decker, Christoph Dehnhardt, Mandy Feng, Wei Gong, Michael Grimwood, Abid Hasan, Angela Hussainkhel, Qi Jia, Stephanie Lee, Jenny Li, Sophia Lin, Andrea Lindgren, Verner Lofstrand, Janette Mezeyova, Rostam Namdari, Karen Nelkenbrecher, Noah Gregory Shuart, Luis Sojo, Shaoyi Sun, Matthew Taron, Matthew Waldbrook, Diana Weeratunge, Steven Wesolowski, Aaron Williams, Michael Wilson, Zhiwei Xie, Rhena Yoo, Clint Young, Alla Zenova, Wei Zhang, Alison J Cutts, Robin P Sherrington, Simon N Pimstone, Raymond Winquist, Charles J Cohen, James R Empfield
Publikováno v:
eLife, Vol 11 (2022)
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target NaV1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A-related epilepsy syndromes (SCN8A-RES), where gain-of-function (G
Externí odkaz:
https://doaj.org/article/ff1c4ccf767e411f85c1b12a0db8fe55
Publikováno v:
Neurology and Therapy. 11:781-796
XEN496 is a novel, granular, immediate-release formulation of ezogabine intended for pediatric use. The objective of this study was to assess the effect of food on the pharmacokinetics (PK) of XEN496 and its N-acetyl metabolite (NAMR) in healthy volu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb46fb6412f14a0f937406dbddad1162
https://doi.org/10.1007/s40120-022-00343-x
https://doi.org/10.1007/s40120-022-00343-x
Autor:
Alison Cutts, Sultan Chowdhury, Laszlo G Ratkay, Maryanne Eyers, Clint Young, Rostam Namdari, Jay A Cadieux, Navjot Chahal, Michael Grimwood, Zaihui Zhang, Sophia Lin, Ian Tietjen, Zhiwei Xie, Lee Robinette, Luis Sojo, Matthew Waldbrook, Michael Hayden, Tarek Mansour, Simon Pimstone, Y. Paul Goldberg, Michael Webb, Charles J. Cohen
Divalent metal transporter 1 (DMT1) cotransports ferrous iron and protons and is the primary mechanism for uptake of non-heme iron by enterocytes. Inhibitors are potentially useful as therapeutic agents to treat iron overload disorders such as heredi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a8fd089f5e95fb80b88ed63e8dd321
https://doi.org/10.1101/2022.09.01.506269
https://doi.org/10.1101/2022.09.01.506269
Autor:
Sultan Chowdhury, David Bogucki, Rostam Namdari, Girish Bankar, Wei Zhang, James Roy Empfield, Matthew Waldbrook, Stephanie M Lee, Lofstrand Verner Alexander, Karen Nelkenbrecher, Samuel J. Goodchild, Rhena Yoo, Noah G. Shuart, Wesolowski Steven Sigmund, Elaine Chang, Mandy Feng, Clint Young, Christoph Martin Dehnhardt, Jenny Li, Zhiwei Xie, Michael Edward Grimwood, Abid Hasan, Sophia Lin, Kristen Burford, Raymond J. Winquist, Charles J. Cohen, Alla Yurevna Zenova, Simon N. Pimstone, Michael R. Wilson, Parisa Karimi Tari, Kuldip Khakh, Celine Dube, Aaron M. Williams, Robin Sherrington, Luis Sojo, Andrea Lindgren, J. P. Johnson, Thilo Focken, Qi Jia, Jean-Christophe Andrez, Shannon Decker, Matthew Taron, Diana Weeratunge, Richard T. Dean, Janette Mezeyova, Shaoyi Sun, Wei Gong, Angela Hussainkhel, Gina de Boer, Alison Jane Cutts
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target NaV1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A-related epilepsy syndromes (SCN8A-RES), where gain-of-function (G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32e2e6674136369f3abcd5070b52e762
https://doi.org/10.1101/2021.08.29.458125
https://doi.org/10.1101/2021.08.29.458125
Autor:
J P, Johnson, Thilo, Focken, Kuldip, Khakh, Parisa Karimi, Tari, Celine, Dube, Samuel J, Goodchild, Jean-Christophe, Andrez, Girish, Bankar, David, Bogucki, Kristen, Burford, Elaine, Chang, Sultan, Chowdhury, Richard, Dean, Gina, de Boer, Shannon, Decker, Christoph, Dehnhardt, Mandy, Feng, Wei, Gong, Michael, Grimwood, Abid, Hasan, Angela, Hussainkhel, Qi, Jia, Stephanie, Lee, Jenny, Li, Sophia, Lin, Andrea, Lindgren, Verner, Lofstrand, Janette, Mezeyova, Rostam, Namdari, Karen, Nelkenbrecher, Noah Gregory, Shuart, Luis, Sojo, Shaoyi, Sun, Matthew, Taron, Matthew, Waldbrook, Diana, Weeratunge, Steven, Wesolowski, Aaron, Williams, Michael, Wilson, Zhiwei, Xie, Rhena, Yoo, Clint, Young, Alla, Zenova, Wei, Zhang, Alison J, Cutts, Robin P, Sherrington, Simon N, Pimstone, Raymond, Winquist, Charles J, Cohen, James R, Empfield
Publikováno v:
eLife. 11
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target Na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3cf389ce4c308fb570995099c2f50504
https://pubmed.ncbi.nlm.nih.gov/35234610
https://pubmed.ncbi.nlm.nih.gov/35234610
Autor:
Andréanne Lortie, Keith Jones, Helen Prior, Samuel S. Chuang, Michael Schmitt, Lars Friis Mikkelsen, Steven Van Cruchten, Sven Jäckel, Björn Jacobsen, Noel Downes, Sofiene Mhedhbi, Jacqueline Kinyamu-Akunda, Joanna Harding, Susanne Mohr, Zuhal Dincer, Rostam Namdari
Publikováno v:
Regulatory toxicology and pharmacology
In drug development, nonclinical safety assessment is pivotal for human risk assessment and support of clinical development. Selecting the relevant/appropriate animal species for toxicity testing increases the likelihood of detecting potential effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2a77a27d35632ac02a82b8e120e3ae
https://repository.uantwerpen.be/docstore/d:irua:9299
https://repository.uantwerpen.be/docstore/d:irua:9299
Autor:
Katie Jane Webster Proctor, Judith Neville, Y P Goldberg, Robin Sherrington, Nicola Anne Price, Michael Fetell, Richard Malamut, Jeffery Vest, Rostam Namdari, Samer Kaber, Simon N. Pimstone
Publikováno v:
The Clinical Journal of Pain
Objective The objective was to evaluate the safety and efficacy of TV-45070 ointment, as a treatment for postherpetic neuralgia, and to explore the response in patients with the Nav1.7 R1150W gain-of-function polymorphism. Materials and methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10a87486de7571f3c3c9fc7f9cca0df
https://doi.org/10.1097/ajp.0000000000000408
https://doi.org/10.1097/ajp.0000000000000408
Autor:
Rostam Namdari, Jianmin Fu, Brian K. Hubbard, Kuldip Khakh, Suzie Ferreira, Michael D. Winther, Zaihui Zhang, Vandna Raina, Duanjie Hou, Natalie Dales, David G. McLaren, Leslie G. Ratkay, Pokrovskaia Natalia, Shaoyi Sun, Monica Mork
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:526-531
We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30298b86448d213fe671561704871195
https://doi.org/10.1016/j.bmcl.2013.12.035
https://doi.org/10.1016/j.bmcl.2013.12.035
Autor:
Y P Goldberg, Rostam Namdari, Michael R. Hayden, Nicola Anne Price, S. N. Pimstone, Charles Jay Cohen, Robin Sherrington
Publikováno v:
Clinical Genetics. 82:367-373
We have utilized a novel application of human genetics, illuminating the important role that rare genetic disorders can play in the development of novel drugs that may be of relevance for the treatment of both rare and common diseases. By studying a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a661802378e279fb587c3de2d5a554a8
https://doi.org/10.1111/j.1399-0004.2012.01942.x
https://doi.org/10.1111/j.1399-0004.2012.01942.x
Autor:
Simon N. Pimstone, James Price, Conrad Winters, Henry Verschoof, Charles Jay Cohen, Nicola Anne Price, Robin Sherrington, Clint Young, Rostam Namdari, Y P Goldberg, Michael R. Hayden, M.H. Lamers
Publikováno v:
Pain, 153, 80-5
Pain, 153, 1, pp. 80-5
Pain, 153, 1, pp. 80-5
Item does not contain fulltext Mutations in the SCN9A gene leading to deficiency of its protein product, Na(v)1.7, cause congenital indifference to pain (CIP). CIP is characterized by the absence of the ability to sense pain associated with noxious s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a348571150a7312357b621ec081131b2
https://doi.org/10.1016/j.pain.2011.09.008
https://doi.org/10.1016/j.pain.2011.09.008